Skip to main content

news

 

Freshfields Bruckhaus Deringer is representing Hong Kong-listed biotech company Henlius on its $691 million take-private deal offer from Shanghai Fosun New Medicine Research Company, which is being advised by Reed Smith.

Kirkland & Ellis offered legal advice to the financial advisor, China International Capital Corporation (CICC), in the deal.

Henlius, established in 2010, was listed in Hong Kong in September 2019. Its product portfolio covers areas such as oncology, autoimmune diseases, and ophthalmic diseases. The company has launched five products in China and has three products approved for international markets. In 2023, the company achieved its first annual profit.

The Freshfields team was led by partners Edward Freeman, Grace Huang, and David Yi.

The Kirkland team was led by corporate partners Joey Chau and Nelson Ni, with assistance from debt finance partners Jacqueline Zheng and Sean Zhang.

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

Deals

Davis Polk, Gibson Dunn advise on $2.3 bln Nippon Paint-AOC deal

by Asian Legal Business《亚洲法律杂志》 |

Davis Polk & Wardwell has advised Japanese paint manufacturer Nippon Paint on its $2.3 billion acquisition of U.S. chemicals formulator AOC from Lone Star Funds, which was represented by Gibson, Dunn & Crutcher.

Deals

Stephenson Harwood, Links advise on $349 mln SG-UK taxi deal

by Asian Legal Business《亚洲法律杂志》 |

Stephenson Harwood has advised Singaporean transport operator ComfortDelGro on its 269-million-pound ($349 million) acquisition of the British private hire cab and courier company Addison Lee, whose shareholders were represented by Linklaters.

Deals

NO&T, STB, AMT, Davis Polk advise on Japan's biggest IPO in 6 years

by Asian Legal Business《亚洲法律杂志》 |

Nagashima Ohno & Tsunematsu and Simpson Thacher & Bartlett have advised Tokyo Metro on its 348.6 billion yen ($2.3 billion) initial public offering, Japan's largest in six years.